ethyl 2-amino-4-(3-methoxyphenyl)thiophene-3-carboxylate | 312289-23-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 噻吩类
• 英文名称: ethyl 2-amino-4-(3-methoxyphenyl)thiophene-3-carboxylate
• 英文别名: 2-amino-4-(3-methoxyphenyl)thiophene-3-carboxylic acid ethyl ester；ethyl 2-amino-4-[3-(methyloxy)phenyl]-3-thiophenecarboxylate
• CAS: 312289-23-9
• 化学式: C₁₄H₁₅NO₃S
• mdl: MFCD01414432
• 分子量: 277.344
• InChiKey: DFRZGBOFFNEAEO-UHFFFAOYSA-N

物化性质

• 沸点：
  418.1±45.0 °C(Predicted)
• 密度：
  1.233±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.6
• 重原子数：
  19
• 可旋转键数：
  5
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.21
• 拓扑面积：
  89.8
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  ethyl 2-amino-4-(3-methoxyphenyl)thiophene-3-carboxylate 在 4-二甲氨基吡啶 、 水 、 potassium hydroxide 作用下， 以 吡啶 、 乙醇 为溶剂， 反应 8.17h， 生成 2-{[(tert-butoxy)carbonyl]amino}-4-(3-methoxyphenyl)thiophene-3-carboxylic acid
  参考文献：
  名称：

  Synthesis and structure–activity relationships of 2-amino-3-carboxy-4-phenylthiophenes as novel atypical protein kinase C inhibitors

  摘要：

  Recent evidence suggests atypical protein kinase C (aPKC) isoforms are required for both TNF- and VEGF-induced breakdown of the blood-retinal barrier (BRB) and endothelial permeability to 70 kDa dextran or albumin. A chemical library screen revealed a series of novel small molecule phenylthiophene based inhibitors of aPKC isoforms that effectively block permeability in cell culture and in vivo. In an effort to further elucidate the structural requirements of this series of inhibitors, we detail in this study a structure-activity relationship (SAR) built on screening hit 1, which expands on our initial pharmacophore model. The biological activity of our analogues was evaluated in models of bona fide aPKC-dependent signaling including NF kappa B driven-gene transcription as a marker for an inflammatory response and VEGF/TNF-induced vascular endothelial permeability. The EC50 for the most efficacious inhibitors (6, 32) was in the low nanomolar range in these two cellular assays. Our study demonstrates the key structural elements that confer inhibitory activity and highlights the requirement for electron-donating moieties off the C-4 aryl moiety of the 2-amino-3-carboxy-4-phenylthiophene backbone. These studies suggest that this class has potential for further development into small molecule aPKC inhibitors with therapeutic efficacy in a host of diseases involving increased vascular permeability and inflammation. (C) 2013 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2013.03.019
• 作为产物：
  描述：

  3-甲氧基苯乙酮 在 水 、 碳酸氢钠 、 sulfur 、 溶剂黄146 、 六甲基二硅氮烷 作用下， 以 四氢呋喃 为溶剂， 反应 82.0h， 生成 ethyl 2-amino-4-(3-methoxyphenyl)thiophene-3-carboxylate
  参考文献：
  名称：

  [EN] NOVEL COMPOUNDS
  [FR] NOUVEAUX COMPOSÉS

  摘要：

  本发明涉及新型NADPH氧化酶II抑制剂及其在治疗由NADPH氧化酶II酶介导的疾病中的应用。

  公开号：

  WO2011075559A1

文献信息

• [EN] THIENOPYRIDONE DERIVATIVES AS AMP-ACTIVATED PROTEIN KINASE (AMPK) ACTIVATORS<br/>[FR] DÉRIVÉS DE THÉNOPYRIDONE COMME ACTIVATEURS DE LA PROTÉINE KINASE DÉPENDANTE DE L'AMP (AMPK)
  申请人：MERCK PATENT GMBH

  公开号：WO2009124636A1

  公开（公告）日：2009-10-15

  The present invention relates to compounds of formula (I) wherein R1, R2 and R3 are as defined in claim 1, including pharmaceutical compositions thereof and for their use in the treatment and/or prevention of diseases and disorders modulated by AMP agonists. The invention is also directed to intermediates and to a method of preparation of compounds of formula (I).

  本发明涉及式(I)的化合物，其中R1、R2和R3如权利要求1所定义，包括其药物组合物以及用于治疗和/或预防由AMP激动剂调节的疾病和紊乱的用途。该发明还涉及中间体和式(I)化合物的制备方法。
• THIENOPYRIDONE DERIVATIVES AS AMP-ACTIVATED PROTEIN KINASE (AMPK) ACTIVATORS
  申请人：Cravo Daniel

  公开号：US20110034505A1

  公开（公告）日：2011-02-10

  The present invention relates to compounds of formula (I) wherein R1, R2 and R3 are as defined in claim 1 , including pharmaceutical compositions thereof and for their use in the treatment and/or prevention of diseases and disorders modulated by AMP agonists. The invention is also directed to intermediates and to a method of preparation of compounds of formula (I).

  本发明涉及式（I）化合物，其中R1、R2和R3如权利要求1所定义，包括其药物组合物以及用于治疗和/或预防由AMP激动剂调节的疾病和紊乱的用途。该发明还涉及中间体和式（I）化合物的制备方法。
• Discovery of Novel, Highly Potent, and Selective Matrix Metalloproteinase (MMP)-13 Inhibitors with a 1,2,4-Triazol-3-yl Moiety as a Zinc Binding Group Using a Structure-Based Design Approach
  作者：Hiroshi Nara、Akira Kaieda、Kenjiro Sato、Takako Naito、Hideyuki Mototani、Hideyuki Oki、Yoshio Yamamoto、Haruhiko Kuno、Takashi Santou、Naoyuki Kanzaki、Jun Terauchi、Osamu Uchikawa、Masakuni Kori

  DOI：10.1021/acs.jmedchem.6b01007

  日期：2017.1.26

  and -14) and tumor necrosis factor-α converting enzyme (TACE). Furthermore, the inhibitor was shown to protect bovine nasal cartilage explants against degradation induced by interleukin-1 and oncostatin M. In this article, we report the discovery of extremely potent, highly selective, and orally bioavailable fused pyrimidine derivatives that possess a 1,2,4-triazol-3-yl group as a novel ZBG for selective

  在对喹唑啉衍生物1和三唑衍生物2与基质金属蛋白酶（MMP）-13催化结构域的配合物的X射线晶体结构进行叠加研究的基础上，得到了一系列新型的具有1,2,4-嘧啶基的稠合嘧啶化合物。设计了三唑-3-基作为锌结合基团（ZBG）。在本文所述和评估的化合物中，31f对MMP-13（IC 50= 0.036 nM）和相对于其他MMP（MMP-1，-2，-3，-7，-8，-9，-10和-14）的选择性（大于1,500倍）和肿瘤坏死因子-α转换酶（TACE）。此外，已证明该抑制剂可保护牛鼻软骨外植体免受白介素-1和制瘤素M诱导的降解。在本文中，我们报告了发现一种具有1,2的极强效，高选择性和口服生物利用度的融合嘧啶衍生物的发现。 ，4-三唑-3-基作为选择性抑制MMP-13的新型ZBG。
• Pharmaceutically active compounds and methods of use
  申请人：——

  公开号：US20030073733A1

  公开（公告）日：2003-04-17

  New fused thiophene compounds are provided and methods of using those compounds for a variety of therapeutic indications. Compounds of the invention are particularly useful for treatment of neuropathic pain.

  提供了新的融合噻吩化合物，并提供了使用这些化合物治疗各种治疗适应症的方法。该发明的化合物特别适用于治疗神经病性疼痛。
• [EN] THIENO [2,3-B] PYRIDINEDIONE ACTIVATORS OF AMPK AND THERAPEUTIC USES THEREOF<br/>[FR] ACTIVATEURS THIÉNO [2,3-B] PYRIDINEDIONE DE L'AMPK ET UTILISATIONS THÉRAPEUTIQUES DE CEUX-CI
  申请人：POXEL

  公开号：WO2011080277A1

  公开（公告）日：2011-07-07

  The invention relates to compounds that are direct activators of AMPK (AMP- activated protein kinase) and their use in the treatment of disorders regulated by activation of AMPK. For instance, compounds according to the invention are useful for the treatment of diabetes, metabolic syndrome, obesity, inflammation, cancer and cardiovascular diseases.

  这项发明涉及直接激活AMPK（AMP-激活蛋白激酶）的化合物及其在治疗受AMPK激活调节的疾病中的应用。例如，根据该发明的化合物可用于治疗糖尿病、代谢综合征、肥胖、炎症、癌症和心血管疾病。